• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VKTX

VKTX

Viking Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD29.33

+0.04 (+0.14%)

Rating:C-

Company Profile

CEO

Brian Lian

IPO Date

2015-04-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$29.13

Prev. Close

$29.29

Day Low

$29.06

Day High

$29.80

52W Low

$22.96

52W High

$43.15

Market Cap

$3.41B

Volume

1.46M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

32.7%

Avg Negative

3.4%

Avg Neutral

63.8%

News Feed

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/28/2021·↓ negative

Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

PRNewsWire·7/28/2021·↑ positive

Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021

PRNewsWire·
7/21/2021
·↑ positive

Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

PRNewsWire·6/24/2021·↑ positive

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

PRNewsWire·6/17/2021·↑ positive

Viking Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire·6/10/2021·↑ positive

Viking Therapeutics: Checking For A Pulse

Seeking Alpha·5/19/2021·↑ positive

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·4/28/2021·↓ negative

Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021

PRNewsWire·4/21/2021·↑ positive

Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

PRNewsWire·4/7/2021·↑ positive